Conference Proceedings
Pre-existing and acquired mechanisms of resistance to lorlatinib in previously treated patients (pts) with ALK plus advanced non-small cell lung cancer (NSCLC)
BJ Solomon, J-F Martini, A Bearz, EH Tan, R Soo, B Besse, TM Bauer, D Shepard, F Toffalorio, A Abbattista, E Felip, AT Shaw, S Viteri, DR Camidge, T Seto, S-HI Ou
ANNALS OF ONCOLOGY | ELSEVIER | Published : 2021
Grants
Funding Acknowledgements
Pfizer Inc.